Clinical trials in the United States have become more complex in the last ten years. A typical Phase III trial now creates about 3.6 million data points, which is three times more than a decade ago. This large amount of data comes from electronic health records (EHR), wearable health devices, genetic information, and patient reports. Handling and studying this much information is very hard for people alone.
Finding patients to join these trials is also a big problem. The National Library of Medicine says that up to 80% of clinical trials do not reach their patient enrollment targets. When recruitment takes too long, it costs more money and slows down getting new treatments to patients. Because clinical trials need to follow strict rules and cost a lot, working efficiently is very important. AI-driven automation and autonomous agents are being used to make trial processes faster and help involve patients better.
Autonomous AI agents are smart computer programs that can do complicated tasks on their own. Unlike basic AI that does only one task, like recognizing images, these agents can combine many types of data, learn from results as they go, and work with little help from people. In healthcare clinical trials, these agents can handle work flows, talk to patients, watch over trial progress, and support the study teams.
New AI platforms, like Accenture’s AI Refinery™ and Salesforce’s Life Sciences Cloud, show how AI agents can reduce the time needed to build and use AI solutions from months or weeks down to just days. These platforms connect different types of data and use smart algorithms to manage trials in real time, making hard trial tasks easier for organizations.
Using these AI agents helps healthcare groups in the U.S. cut costs, finish trials faster, and get better results. Speeding up trial tasks helps patients, researchers, and sponsors get new treatments more quickly.
Getting patients involved is very important for clinical trials to work well. Patients who take part are more likely to follow the rules, show up to visits, and give good data. Autonomous AI agents help by making communication personal and giving help right away:
These AI interactions help create a patient-centered trial where participating is easier and safer.
Automating workflows is a main feature of autonomous AI agents in clinical trials. These systems make operations more efficient by linking many people involved, like sponsors, clinical research groups, trial sites, and patients.
For medical practice administrators and IT managers, these automations mean fewer problems during trials, less stress on clinical staff, and better oversight. Automating routine tasks lets study teams focus on important work like medical decisions and patient care.
Despite clear benefits, using autonomous AI agents has challenges:
Many healthcare groups in the U.S. deal with these issues by working with expert AI companies, standardizing data, and having teams watch ethical AI use. This approach helps get the most from AI while avoiding problems.
Some organizations lead in using AI for clinical trial management:
These platforms show how AI agents can be used across different U.S. healthcare places, from big academic centers to smaller hospitals.
Medical practice administrators, owners, and IT managers in the U.S. have an important role in clinical trial success. Autonomous AI agents offer useful tools to lower admin work, improve patient involvement, and speed up trials. By automating patient recruitment, monitoring, and workflow, AI systems solve long-time problems in research and raise the chance of successful trial results.
Understanding both the benefits and challenges of AI helps healthcare leaders make smart choices about technology investments. Working with trusted AI vendors experienced in healthcare, focusing on rule compliance, and training staff will help AI agents fit well into trial operations. As AI improves, it is likely to become a normal part of supporting clinical research in the U.S., improving both patient experience and medical progress.
For medical practices in the U.S. involved in clinical trials, keeping up with advances in autonomous AI agents and planning how to include them in current workflows will be important for managing trials well in the future.
Accenture’s AI Refinery for Industry is a platform with 12 initial AI agent solutions designed to help organizations rapidly build, deploy, and customize AI agent networks. These agents enhance workforce capabilities, address industry-specific challenges, and accelerate business value through automation and workflow integration.
AI Refinery leverages NVIDIA AI Enterprise software, including NeMo, NIM microservices, and AI Blueprints, reducing AI agent development time from months or weeks to days. This enables faster customization using an organization’s data and quick realization of AI benefits.
The first 12 solutions focus on varied industries: revenue growth management in consumer goods, clinical trial management in life sciences, asset troubleshooting in industrial sectors, and B2B marketing automation, among others to solve critical, industry-specific challenges.
AI agents function as clinical trial companions, personalizing trial plans, guiding patients and clinicians throughout the trial, answering real-time queries, reducing dropout rates, and improving trial success by enhancing participant engagement and operational clarity.
They enable engineers to swiftly resolve equipment issues by correlating real-time data, performing automated inspections, and providing actionable recommendations. This shifts maintenance from reactive to proactive, reduces downtime, and enhances decision-making for operational excellence.
Agentic AI refers to autonomous AI agents capable of solving complex, multi-step problems. This next AI wave boosts productivity by managing workflows independently, allowing enterprises to innovate and optimize efficiency at scale.
Customization allows AI agents to be tailored with organization-specific data and business processes. This ensures AI agents effectively address unique clinical workflows, patient needs, and operational goals, delivering personalized, relevant support.
Accenture aims to grow the AI Refinery agent solution portfolio to over 100 industry-specific agents by year-end, broadening deployment across various sectors and use cases to accelerate AI adoption and value creation.
AI agents analyze multi-source data, deliver audience insights, personalize messaging, optimize campaign strategies, and uncover asset reuse opportunities, enabling marketing staff to execute smarter, faster, and more effective campaigns.
The platform is built on an extensive technology stack from NVIDIA, including AI Enterprise software, NeMo, NIM microservices, and AI Blueprints. This collaboration delivers scalable, enterprise-grade AI agent capabilities integrated within SaaS and cloud ecosystems.